Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

828
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
828
Sex-linked Disorders01:43

Sex-linked Disorders

98.3K
Like autosomes, sex chromosomes contain a variety of genes necessary for normal body function. When a mutation in one of these genes results in biological deficits, the disorder is considered sex-linked.
98.3K
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

1.9K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
1.9K
Pedigree Analysis01:35

Pedigree Analysis

82.3K
Overview
82.3K
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

109
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
109
Formation of Muscle Fibers from Myoblasts01:13

Formation of Muscle Fibers from Myoblasts

3.8K
De novo myogenesis, or the formation of muscle fibers, begins during the early embryonic stages. The skeletal muscle is formed from somites– blocks of embryonic cell layers. The somites are further divided into dermatomes, myotomes, sclerotomes, and syndetomes. Among these, the myotomes give rise to muscle fibers.
Muscle progenitor cells (MPCs) are formed from the myotomes. MPCs express genes that encode the transcription factors Pax3 and Pax7. Along with Pax 3/7, other transcription...
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A case of punctate DWI hyperintense lesions concurrent with ARIA-E during donanemab therapy.

Journal of the neurological sciences·2026
Same author

Case Report: Anti-LGI1 encephalitis during FcRn inhibition with efgartigimod for myasthenia gravis: implications for the limitations of IgG recycling blockade.

Frontiers in immunology·2026
Same author

A Rare Association of Anti-SRP Antibody-Positive Immune-Mediated Necrotizing Myopathy and Sjögren Disease: Two Case Reports.

Muscle & nerve·2026
Same author

Asthma-like bronchodilator responsiveness in patients with neuronal intranuclear inclusion disease.

Scientific reports·2026
Same author

Circadian disruption and its clinical implications in Parkinson's disease: A Narrative review.

Sleep medicine·2026
Same author

Pathogenic CGG expansions in oculopharyngodistal myopathy exhibit distinct characteristics of each causative gene on the flanking sequences as well as methylation status.

Genome medicine·2026
Same journal

[Neuropathological Autopsies in Japan: Current Scenario and Challenges].

Brain and nerve = Shinkei kenkyu no shinpo·2026
Same journal

[Telemedicine and Digital Technologies in Neurological Intractable Diseases].

Brain and nerve = Shinkei kenkyu no shinpo·2026
Same journal

[Disaster Countermeasures for Intractable Neurological Disease].

Brain and nerve = Shinkei kenkyu no shinpo·2026
Same journal

[Supporting Health Care Transition for Patients with Childhood-Onset Chronic Conditions: Within Intractable Disease Care in Japan].

Brain and nerve = Shinkei kenkyu no shinpo·2026
Same journal

[Multidisciplinary Collaboration between Hospitals and Clinics at the University Hospital and the Core Hospital for the Treatment of Intractable Diseases].

Brain and nerve = Shinkei kenkyu no shinpo·2026
Same journal

[The Role of Coordinators for Intractable Diseases in Japan].

Brain and nerve = Shinkei kenkyu no shinpo·2026
See all related articles

Related Experiment Video

Updated: May 13, 2025

Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies
14:10

Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies

Published on: January 31, 2013

32.8K

[Hereditary Muscle Disorders].

Kazuma Sugie1

  • 1Department of Neurology, Nara Medical University School of Medicine.

Brain and Nerve = Shinkei Kenkyu No Shinpo
|May 12, 2025
PubMed
Summary
This summary is machine-generated.

Recent research advances are making hereditary muscle diseases, like Duchenne muscular dystrophy, treatable. Early diagnosis is crucial for accessing these new therapies and improving patient outcomes.

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.0K
Tissue Triage and Freezing for Models of Skeletal Muscle Disease
05:58

Tissue Triage and Freezing for Models of Skeletal Muscle Disease

Published on: July 15, 2014

39.9K

Related Experiment Videos

Last Updated: May 13, 2025

Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies
14:10

Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies

Published on: January 31, 2013

32.8K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.0K
Tissue Triage and Freezing for Models of Skeletal Muscle Disease
05:58

Tissue Triage and Freezing for Models of Skeletal Muscle Disease

Published on: July 15, 2014

39.9K

Area of Science:

  • Neurology
  • Genetics
  • Pharmacology

Background:

  • Hereditary muscle diseases, including muscular dystrophies and myopathies, are often rare and challenging to manage.
  • Significant research progress is transforming previously untreatable conditions into manageable ones.

Purpose of the Study:

  • To highlight recent therapeutic advancements in hereditary muscle diseases.
  • To emphasize the growing importance of accurate diagnosis for accessing novel treatments.
  • To underscore the need for increased research and clinical focus on neuromuscular disorders.

Main Methods:

  • Review of recent scientific literature and clinical trial outcomes.
  • Analysis of newly approved therapeutic agents for specific muscle diseases.
  • Discussion of diagnostic advancements and their clinical implications.

Main Results:

  • Emergence of new, effective treatments for previously intractable hereditary muscle diseases.
  • Approval of a novel drug for Duchenne muscular dystrophy, offering new hope.
  • Increased potential for improved patient outcomes through timely and accurate diagnosis.

Conclusions:

  • The landscape of hereditary muscle disease treatment is rapidly evolving towards greater efficacy.
  • Accurate and timely diagnosis is paramount to ensure patients benefit from emerging therapies.
  • Continued investment in research and clinical expertise is vital for advancing neuromuscular disease care.